VanEck Biotech ETF Rating $179.18 +2.53 (+1.43%) Closing price 03:51 PM EasternExtended Trading$178.82 -0.36 (-0.20%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock VanEck Biotech ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BBH Aggregate RatingModerate Buy 2.65Holdings in BBH have an aggregate rating of Moderate Buy based on 509 analyst ratings issued in the past year covering 25 companies (100.0% of the portfolio).BBH Aggregate Price Target$179.18High Prediction$179.18Average Prediction$179.18Low Prediction$179.18Holdings in BBH have an aggregate price target of $179.18 and a range of $179.18 to $179.18 covering 25 companies (100.0% of the portfolio).BBH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy16 Moderate Buy rating(s)Hold8 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by VanEck Biotech ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 BBH Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings12.94%AMGNAmgen$303.33+1.5%4.5631 of 5 stars2.32$305.50 0.7%19Positive NewsAnalyst Upgrade11.73%GILDGilead Sciences$123.11+0.2%4.906 of 5 stars2.86$120.04 -2.5%28Positive NewsAnalyst ForecastInsider Trade9.45%VRTXVertex Pharmaceuticals$419.10+0.5%4.8197 of 5 stars2.62$494.38 18.0%29Positive News5.14%REGNRegeneron Pharmaceuticals$576.77-0.2%4.8603 of 5 stars2.79$817.88 41.8%29Positive NewsGap Down4.94%ARGXargenex$849.46+0.7%3.3716 of 5 stars3.00$817.53 -3.8%244.76%IQVIQVIA$212.30+3.8%4.6113 of 5 stars2.83$234.57 10.5%24Positive News4.68%ALNYAlnylam Pharmaceuticals$491.22+2.0%4.0671 of 5 stars2.82$463.08 -5.7%28Analyst Forecast4.54%ONCBeOne Medicines$318.59+0.7%3.0157 of 5 stars2.90$345.60 8.5%10Positive NewsAnalyst Forecast4.49%INSMInsmed$167.91+1.3%3.0679 of 5 stars2.86$152.88 -9.0%21Positive NewsAnalyst Forecast3.96%NTRANatera$188.60+3.8%2.1379 of 5 stars2.89$196.81 4.4%19Short Interest ↑3.61%UTHRUnited Therapeutics$432.69-0.1%4.7352 of 5 stars2.60$457.21 5.7%15Positive NewsAnalyst ForecastInsider Trade3.56%ICLRIcon$188.45+1.8%4.2135 of 5 stars2.68$210.64 11.8%19Positive NewsUpcoming Earnings3.53%BIIBBiogen$146.63+2.5%4.7538 of 5 stars2.32$180.69 23.2%31Analyst Revision2.52%ILMNIllumina$99.50+4.2%4.7827 of 5 stars2.11$115.25 15.8%192.42%BNTXBioNTech$107.95+2.7%2.7056 of 5 stars2.64$134.32 24.4%142.37%NBIXNeurocrine Biosciences$141.33+0.9%4.6553 of 5 stars2.86$163.72 15.8%21Positive NewsAnalyst Forecast2.19%INCYIncyte$86.17-1.6%4.5969 of 5 stars2.32$84.79 -1.6%19Analyst Downgrade2.03%TEMTempus AI$92.45+5.3%2.3041 of 5 stars2.47$74.77 -19.1%15Analyst ForecastGap Down1.93%MRNAModerna$27.24+4.7%4.289 of 5 stars2.00$39.93 46.6%21Analyst ForecastOptions VolumeAnalyst Revision1.79%QGENQiagen$48.69+0.9%4.182 of 5 stars2.30$49.69 2.1%10Positive News1.74%TECHBio-Techne$62.54+1.1%4.6395 of 5 stars2.63$70.58 12.9%161.47%BMRNBioMarin Pharmaceutical$53.07-0.4%4.9722 of 5 stars2.55$93.26 75.7%221.42%CRLCharles River Laboratories International$184.10+3.1%4.4684 of 5 stars2.35$181.29 -1.5%17Analyst Forecast1.41%EXASExact Sciences$62.73+2.4%4.4198 of 5 stars2.92$69.19 10.3%24Analyst Revision1.33%RGENRepligen$154.54+1.3%4.5616 of 5 stars2.73$169.62 9.8%15Analyst Downgrade This page (NASDAQ:BBH) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredWhat the hell is going on, America?America’s $37.5 trillion debt spiral, soaring deficits, and repeated credit downgrades are exactly what Porter...Porter & Company | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredGold surges past $4,200 … but this has beat gold by 1,000xGold has surged past $4,200 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share VanEck Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
